[go: up one dir, main page]

PE20200383A1 - INTENTIONALLY SELECTED COMPOSITIONS INCLUDING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENS - Google Patents

INTENTIONALLY SELECTED COMPOSITIONS INCLUDING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENS

Info

Publication number
PE20200383A1
PE20200383A1 PE2019001790A PE2019001790A PE20200383A1 PE 20200383 A1 PE20200383 A1 PE 20200383A1 PE 2019001790 A PE2019001790 A PE 2019001790A PE 2019001790 A PE2019001790 A PE 2019001790A PE 20200383 A1 PE20200383 A1 PE 20200383A1
Authority
PE
Peru
Prior art keywords
purified
terpens
compositions including
cannabinoids
selected compositions
Prior art date
Application number
PE2019001790A
Other languages
Spanish (es)
Inventor
Kurt Levy
Jonathan Michael Cooper
Jonathan Reed Martin
Brian Geoffrey Reid
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/616,874 external-priority patent/US20170266153A1/en
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of PE20200383A1 publication Critical patent/PE20200383A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

Referido a una composicion que comprende un primer cannabinoide purificado; y un compuesto elegido de un segundo cannabinoide purificado o un primer terpeno purificado. En donde el primer terpeno purificado se elige entre 7,8-dihidro-alfa-ionona, acetanisol, limoneno, entre otros; el primer cannabinoide purificado se elige entre acido cannabigerolico (CBGA), cannabigerol (CBG), tetrahidrocannabinol (THC), entre otros. En donde dicha composicion tiene una pureza superior al 80 % y su formulacion comprende combinaciones intencionalmente disenadas de proporciones y concentraciones no naturales.Refers to a composition comprising a first purified cannabinoid; and a compound chosen from a second purified cannabinoid or a first purified terpene. Wherein the first purified terpene is chosen from 7,8-dihydro-alpha-ionone, acetanisole, limonene, among others; The first purified cannabinoid is chosen from cannabigerolic acid (CBGA), cannabigerol (CBG), tetrahydrocannabinol (THC), among others. Wherein said composition has a purity greater than 80% and its formulation comprises intentionally designed combinations of unnatural proportions and concentrations.

PE2019001790A 2017-03-01 2018-03-01 INTENTIONALLY SELECTED COMPOSITIONS INCLUDING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENS PE20200383A1 (en)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201762465688P 2017-03-01 2017-03-01
US201762469415P 2017-03-09 2017-03-09
US201762475153P 2017-03-22 2017-03-22
US201762477990P 2017-03-28 2017-03-28
US201762489360P 2017-04-24 2017-04-24
US201762490465P 2017-04-26 2017-04-26
US201762490567P 2017-04-26 2017-04-26
US201762491160P 2017-04-27 2017-04-27
US201762491175P 2017-04-27 2017-04-27
US201762491980P 2017-04-28 2017-04-28
US201762491899P 2017-04-28 2017-04-28
US201762509651P 2017-05-22 2017-05-22
US201762510229P 2017-05-23 2017-05-23
US201762510660P 2017-05-24 2017-05-24
US201762510672P 2017-05-24 2017-05-24
US201762511218P 2017-05-25 2017-05-25
US15/616,874 US20170266153A1 (en) 2015-02-27 2017-06-07 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
PCT/US2018/020440 WO2018160827A1 (en) 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes

Publications (1)

Publication Number Publication Date
PE20200383A1 true PE20200383A1 (en) 2020-02-24

Family

ID=63370542

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001790A PE20200383A1 (en) 2017-03-01 2018-03-01 INTENTIONALLY SELECTED COMPOSITIONS INCLUDING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENS

Country Status (10)

Country Link
EP (1) EP3589129A4 (en)
CN (1) CN110582206A (en)
AU (1) AU2018227544A1 (en)
BR (1) BR112019018088A2 (en)
CA (1) CA3054690A1 (en)
CO (1) CO2019009413A2 (en)
IL (1) IL268929A (en)
MX (1) MX2019010370A (en)
PE (1) PE20200383A1 (en)
WO (1) WO2018160827A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458906B2 (en) 2018-01-23 2025-11-04 High Sierra Technologies, Inc. Methods of modifying a naturally occurring cannabis raw plant material, a purified cannabis product from a naturally occurring cannabis raw plant material, and a modified cannabis product from a naturally occurring cannabis raw plant material
US10737198B2 (en) 2018-01-23 2020-08-11 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
IL266151A (en) * 2019-04-18 2019-07-31 Kanabo Res Ltd Diluents for compositions of cannabinoids
CA3148236A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
CN114980882A (en) * 2019-11-26 2022-08-30 乐康瑞德有限公司 Synergistic combination of cannabinoid and lycopene anti-inflammatory
CN115605289A (en) * 2020-04-29 2023-01-13 利加尔有限合伙公司（Nz） Imprinted polymers and methods of use
EP4188915A1 (en) * 2020-07-27 2023-06-07 Canopy Growth Corporation Methods of synthesizing cannabielsoin and analogs thereof
US20240342197A1 (en) * 2021-01-29 2024-10-17 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
CN113368086B (en) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 Cannabinoid composition and its application in preparation of medicine for treating neurodegenerative diseases such as Parkinson and Alzheimer
WO2023245185A1 (en) * 2022-06-17 2023-12-21 New Growth Brands, Inc. Compositions comprising cannabinoids and methods of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019322A1 (en) * 2009-04-30 2010-11-11 The Health Concept Gmbh Process for the preparation of synthetic cannabinoids
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (en) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of plant cannabinoid cannabinol (CBDV) for the treatment of epilepsy
CA2931039C (en) * 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MX2017010872A (en) * 2015-02-27 2018-05-07 Ebbu Llc Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral.

Also Published As

Publication number Publication date
CN110582206A (en) 2019-12-17
CO2019009413A2 (en) 2019-09-09
EP3589129A1 (en) 2020-01-08
IL268929A (en) 2019-10-31
AU2018227544A1 (en) 2019-08-29
CA3054690A1 (en) 2018-09-07
BR112019018088A2 (en) 2020-03-24
WO2018160827A1 (en) 2018-09-07
EP3589129A4 (en) 2020-11-25
MX2019010370A (en) 2019-10-22

Similar Documents

Publication Publication Date Title
PE20200383A1 (en) INTENTIONALLY SELECTED COMPOSITIONS INCLUDING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENS
PE20190318A1 (en) ORALLY ADMINISTRABLE COMPOSITION
EA202092582A1 (en) CANNABIDIOL PREPARATIONS AND THEIR APPLICATION
SV1999000072A (en) STABILIZED COMPOSITIONS
MX2020003934A (en) Use of cannabidiol in combination with 5-ht2b receptor agonists or amphetamins in the treatment of epilepsy.
ES2721148T3 (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use
BRPI0717970C1 (en) 11betahsd1 inhibitor compound, pharmaceutical composition, and use of the compound
AR089211A1 (en) LOW VISCOSITY Aqueous FRACTURING FLUID
CL2017001983A1 (en) Pharmaceutical compositions for combination therapy.
CO6220926A2 (en) TOPIC PHARMACEUTICAL FORMULATION FOR THE APPLICATION OF AN NON-SPHERIDAL ANTI-INFLAMMATORY PHARMACO (NSAID)
CR11316A (en) DERIVED FROM URACILO OR TIMINA FOR THE TREATMENT OF HEPATITIS C.
BR112014029754B1 (en) surfactant solutions containing n-methyl-noleylglucamines and n-methyl-n-c12-c14 acylglucamines and their use, process for producing cosmetic compositions and composition
BRPI0410660A (en) 2-amino-pyridine derivatives as ß2 adrenoreceptor agonists
AR059927A1 (en) METHODS FOR THE STABILIZATION OF UNSTABLE COMPOSITIONS TO OXIDATION AND STABILIZED OPHTHALM COMPOSITIONS
PE20200478A1 (en) NEW FORMULATIONS AND COMPOSITIONS OF CANNABIS IN TABLETS AND METHODS FOR THEIR PREPARATION
CL2023001745A1 (en) Pharmaceutical composition of dual glp-1/glp-2 agonists
CL2023001747A1 (en) Pharmaceutical composition of dual glp-1/glp-2 agonists
BR112018012952A2 (en) personal care compositions
UY38941A (en) NEW SULFILIMINS OR SULFOXIMINS CONTAINING HETEROCYCLIC FUNGICIDE COMPOUNDS
BR112013019394A2 (en) use of an agent
CO2023000239A2 (en) Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
CL2019002516A1 (en) Cosmetic compositions for skin care.
BR112013022975A2 (en) compositions containing copolymers
MX2023006281A (en) PHARMACEUTICAL COMPOSITION OF DUAL GLP-1/GLP-2 AGONISTS.
BR0318411A (en) non-toxic mucous disinfectant containing isopropyl alcohol, sesame oil, aloe and lemon oil